Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

Conditions

• Dermatitis, Atopic

Eligibility Criteria

Sex

ALL

Age

12 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Dupilumab — DRUG
  Dupixent 1 dose at Baseline required for eligibility; otherwise, no therapeutic intervention required during the course of the study. In addition to (or substituting for) DUPIXENT®, participants may receive marketed drugs as deemed necessary by their physicians for the treatment of AD or comorbid conditions.

Study Details

A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)

Key Dates

Start date

Apr 6, 2018

Status verified

Dec 2025

Primary completion

Mar 30, 2027

Completion

Mar 30, 2027

Study Design

Enrollment

858 participants (actual)

Primary Outcome Measure

Registry Assessment: Baseline Characteristics [ Time Frame: At baseline (day when DUPIXENT treatment is initiated) ]

Locations (93)

Find similar trials in Birmingham, AL

Related Studies

• Effects of Treatments on Atopic Dermatitis
  PHASE2 · Recruiting · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Bethesda, Maryland
• The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
  Recruiting · Nexgen Dermatologics, Inc. · Boynton Beach, Florida
• Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
  Recruiting · Pfizer · New York, New York
• A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
  PHASE2 · Recruiting · Janssen Research & Development, LLC · Houston, Texas